Welcome to our dedicated page for Puma Biotechnology news (Ticker: PBYI), a resource for investors and traders seeking the latest updates and insights on Puma Biotechnology stock.
Puma Biotechnology reports developments for a biopharmaceutical company built around oncology drug commercialization and development. Company news commonly centers on NERLYNX®, its oral neratinib product for HER2-positive breast cancer, including net product revenue, cost of sales, royalty revenue and financial outlook tied to demand for the therapy.
Updates also cover alisertib, a selective, orally administered aurora kinase A inhibitor licensed for development and commercialization. Puma describes the ALISCA™-Lung1 Phase II trial in extensive-stage small cell lung cancer and the ALISCA™-Breast1 Phase II trial in HER2-negative, HR-positive metastatic breast cancer, along with employee inducement equity awards under Nasdaq Listing Rule 5635(c)(4) and investor conference activity.
Puma Biotechnology (NASDAQ: PBYI) announced the publication of Phase III ExteNET trial results focusing on neratinib's efficacy in HER2-positive, hormone receptor-positive early stage breast cancer. Published in Clinical Breast Cancer, results indicate a 5.1% improvement in 5-year invasive disease-free survival (HR=0.58) in patients treated within a year of adjuvant trastuzumab. Additionally, patients at high risk of recurrence showed a 7.4% improvement (HR=0.60). Common adverse effects included diarrhea (39%) and vomiting (4%).
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced on October 1, 2020, the approval of inducement restricted stock unit awards totaling 12,375 shares for two new non-executive employees. These awards, granted under the 2017 Employment Inducement Incentive Award Plan, will vest over three years, incentivizing employee retention and aligning interests with shareholders. Additionally, Puma focuses on developing innovative cancer care products, including NERLYNX®, which has received FDA approval for treating breast cancer.